Biopharma | May 24, 2025
Sun Pharma to raise stake in US-based Pharmazz to 22.7%
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
For the full year FY25, net profit soared 12x to Rs 345 crore
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Subscribe To Our Newsletter & Stay Updated
